NCT00825721

Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract

A Randomized, Placebo-Controlled, Single-Masked, Dose-Ranging Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataracts

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 81 (actual)
• Sponsor: Chakshu Research, Inc. · Industry
• Sex: All
• Age: 35 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract

Conditions

• Nuclear Cataract

Interventions

Type	Name	Description
DRUG	LiquiTears	4 drops applied daily for 360 days
DRUG	C-KAD Ophthalmic Solution	4 drops applied daily for 360 days
DRUG	C-KAD Ophthalmic Solution	4 drops applied daily for 360 days
DRUG	C-KAD Ophthalmic Solution	4 drops applied daily for 360 days

Timeline

• Start date: 2007-11-01
• Primary completion: 2009-08-01
• Completion: 2009-09-01
• First posted: 2009-01-21
• Last updated: 2009-01-21

Locations

1 site across 1 country: Nepal